Analysis Of Income And Expense [Abstract]

Mithra Pharmaceuticals S.A. - Filing #3183077

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	66,997,000 EUR	—	—	—	—	—	22,668,000 EUR	—
Material income and expense [abstract]
Research and development expense	—	—	64,041,000 EUR	—	—	—	—	—	85,243,000 EUR	—
Selling, general and administrative expense [abstract]
Selling expense	—	—	2,100,000 EUR	—	—	—	—	—	1,871,000 EUR	—
General and administrative expense	—	—	14,675,000 EUR	—	—	—	—	—	12,515,000 EUR	—
Income tax relating to components of other comprehensive income [abstract]
Income tax relating to components of other comprehensive income that will be reclassified to profit or loss	—	—	2,612,000 EUR	—	—	—	—	—	3,597,000 EUR	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	- EUR	18,298,000 EUR	77,918,000 EUR	59,620,000 EUR	- EUR	17,300,000 EUR	- EUR	- EUR	134,175,000 EUR	116,875,000 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	—	77,918,000 EUR	—	—	—	—	—	134,175,000 EUR	—
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests	—	—	- EUR	—	—	—	—	—	- EUR	—